Professional Documents
Culture Documents
Increase in Awareness about Hereditary Angioedema and Novel Pipeline Drugs to Drive
Market
Government organizations and other agencies are creating public awareness through
various campaigns regarding the diagnosis, treatment, and care of hereditary angioedema.
Moreover, the prevalence of rare diseases across the world is increasing, and most of these
are genetic disorders.
The U.S. Hereditary Angioedema Association (U.S. HAEA) organized a fundraising event
and other campaigns in September 2017 to create awareness about the disorder within the
community. Such campaigns boost the growth of the global hereditary angioedema
treatment market.
Promising pipeline drugs and novel therapies by major companies are also fueling the
growth of the global hereditary angioedema treatment market.
For instance, BioCryst Pharmaceuticals has developed an oral drug - BCX7353 - for the
prophylactic treatment of HAE, which has completed the phase II clinical trial.
Moreover, increase in the intensity of attacks of severe edema due to high estrogen
levels and rise in the usage of ACE inhibitors that trigger an attack of HAE are the major
factors driving the global hereditary angioedema treatment market.
The global hereditary angioedema treatment market has been segmented into three
major regions: North America, Europe, and Rest of the World.
North America accounted for a major share of the global hereditary angioedema
treatment market in 2018, and is projected to dominate the market during the forecast
period.
High prevalence of hereditary angioedema, comparatively better reported ratio for
diseases, high healthcare expenditure, and availability of specialty HAE products are the
major factors boosting the growth of the hereditary angioedema treatment market North
America.
Rest of the World is anticipated to be a highly lucrative hereditary angioedema
treatment market during the forecast period, due to factors such as rise in the number of
reported cases of hereditary angioedema in recent times, increase in awareness in
developing countries about rare diseases, and introduction of novel therapies.
Shire plc (Takeda Pharmaceutical Company Limited), CSL Limited, and Pharming Group
NV are leading players in the global hereditary angioedema treatment market.
The global hereditary angioedema treatment market is projected to be driven by novel
therapies and pipeline products during the forecast period. These pipeline products are in
various clinical trial phases, and are expected to be launched in the next few years.
New product approvals for specific indications, robust R&D expenditure & pipeline
products, and mergers & acquisitions are the key strategies adopted by major players in the
global hereditary angioedema treatment market
Ionis Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals
Ltd., and Attune Pharmaceuticals have several different products in the pipeline for the
treatment of HAE.
https://www.prnewswire.com/news-releases/rising-number-of-sports-injuries-and-
consequent-surgeries-to-help-medical-dynamometer-market-to-reach-us984-6-mn-valuation-
by-2026--finds-tmr-301187230.html
https://www.prnewswire.com/news-releases/care-delivery-models-in-telemedicine-market-
aim-at-reducing-patient-burden-market-to-clock-robust-cagr-of-14-0-from-2019-to-2027-tmr-
301190294.html
https://www.prnewswire.co.uk/news-releases/closed-system-transfer-devices-market-to-
observe-notable-growth-due-to-increase-in-use-of-oncology-drugs-and-emergence-of-novel-
protocols-in-pharmaceutical-industry-says-tmr-825812545.html
About Us
TMR’s data repository is continuously updated and revised by a team of research experts so
that it always reflects the latest trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous primary and secondary research
techniques to develop distinctive data sets and research material for business reports.
Contact